Akebia Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 56.2 million compared to USD 55.78 million a year ago. Net income was USD 0.613 million compared to net loss of USD 6.07 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.34 USD | +0.75% | -1.47% | +8.06% |
Apr. 23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.06% | 281M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- AKBA Stock
- News Akebia Therapeutics, Inc.
- Akebia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023